A Link to Study at Bottom
The Boulware et al randomized clinical trial confirms the efficacy of post-exposure hydroxychloroquine through additional study data following its publication in the New England Journal of Medicine. In our June 4 article relating to the study by Dr. Boulware (Minnesota) published in the NEJM and concluding that hydroxychloroquine did not work when the molecule was given to people after post-exposure to the virus, we had shown that in fact, the data showed significant efficacy when the molecule was given to patients on D + 1, D + 2 or D + 3 after exposure to the virus. In addition, Doctor Boulware had omitted to mention his links of interest with the Gilead laboratory.
Dr Márcio Watanabe from the Statistics Department of the Universidade Federal Fluminense has just confirmed the analyzes that we published on June 4.
In particular, he points to the statistical method used to say whether the effect of the drug is significant or not. Remember that Marcio Watanabe has a doctorate in statistics and therefore his opinion on the issue is very relevant.
In the present problem, the question to be answered is whether the treatment is able to reduce the incidence of symptomatic patients as opposed to the null hypothesis H0 that it will be as good as a placebo. Thus, a one-sided test is the natural choice of the alternative H1 hypothesis in this problem, unlike the two-sided test adopted in their study. »
Here is a summary of his findings on the data from the Boulware study.
“By doing an analysis with these time-dependent data by adopting a simple regression analysis, he concludes that this randomized, double-blind, placebo-controlled trial has statistical evidence, at a 99% confidence level, that the treatment of Covid-19 patients with hydroxychloroquine is effective in reducing the appearance of symptoms if used before or immediately after exposure to the virus.
Click this Link to PDF File Source: Archyde